Plerixafor: what we still have to learn.

about

Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial.Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes.

P2860

Q40490106-A48F283D-CF5E-4002-B3BE-0B7E81150744 Q50959656-6A5A57EC-629B-493E-8207-D9C6AF8B5BC9

P2860

Plerixafor: what we still have to learn.

Item

http://www.wikidata.org/entity/Q48747463

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Plerixafor: what we still have to learn.

@en

Plerixafor: what we still have to learn.

@nl

type

Item

label

Plerixafor: what we still have to learn.

@en

Plerixafor: what we still have to learn.

@nl

prefLabel

Plerixafor: what we still have to learn.

@en

Plerixafor: what we still have to learn.

@nl

P1476

Plerixafor: what we still have to learn.

@en

P2093

Angelo Gardellini

http://www.w3.org/2001/XMLSchema#string

Daniele Laszlo

http://www.w3.org/2001/XMLSchema#string

Francesco Lanza

http://www.w3.org/2001/XMLSchema#string

P2860

Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation.

Haematopoietic stem cell release is regulated by circadian oscillations

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

Phase I study of the safety and pharmacokinetics of plerixafor in children undergoing a second allogeneic hematopoietic stem cell transplantation for relapsed or refractory leukemia.

Plerixafor for mobilization of blood stem cells in autologous transplantation: an update.

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.

Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.

New strategies for stem cell mobilization.

P304

143-147

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1517/14712598.2015.971750

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Massimo Martino

P577

2014-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266946668

http://www.w3.org/2001/XMLSchema#string

P698

25315706

http://www.w3.org/2001/XMLSchema#string

Plerixafor: what we still have to learn.

about

P2860

P2860

Plerixafor: what we still have to learn.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698